SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Atom Therapeutics Doses First Patient in Phase 2 Kidney Disease Trial

Atom Therapeutics said the first patient has been dosed in a Phase 2 trial of lingdolinurad (ABP-671) for chronic kidney disease with hyperuricemia.

Related stories